---
title: Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)
nct_id: NCT01643447
overall_status: COMPLETED
phase: NA
sponsor: Eastern Hepatobiliary Surgery Hospital
study_type: INTERVENTIONAL
primary_condition: Hepatocellular Carcinoma
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01643447.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01643447"
ct_last_update_post_date: 2016-03-31
last_seen_at: "2026-05-12T06:43:04.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

**Official Title:** A Prospective Randomized Trial Comparing Ulinastatin's Drug Protection in Hepatocellular Carcinoma(HCC)Patients'Postoperative Hepatic Failure

**NCT ID:** [NCT01643447](https://clinicaltrials.gov/study/NCT01643447)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Conditions:** Hepatocellular Carcinoma
- **Start Date:** 2012-05
- **Completion Date:** 2015-04
- **CT.gov Last Update:** 2016-03-31

## Brief Summary

The purpose of this study is to confirm that Ulinastatin is a safe and effective drug and it can reduce the incidence of postoperative hepatic failure in HCC patients. To evaluate that Ulinastatin can improve survival in HCC patients or not.

## Detailed Description

Hepatocellular carcinoma (HCC), a serious disease with high incidence at home and abroad, still shows a rising trend. Postoperative hepatic failure remains a major reason of liver resection's failure.

• As broad spectrum of enzyme inhibitors, Ulinastatin has the valid therapeutical effect of hepatic failure and hepatic ischemia-reperfusion injury in animal experiment. And it restrain inflammatory mediator to release. But it's lack of clinical evidence that Ulinastatin reduce the incidence of postoperative hepatic failure in HCC patients The purpose of the study is to assess the effort for comparing Ulinastatin's drug protection in patients with hepatocellular carcinoma (HCC) for postoperative hepatic failure and to evaluate that Ulinastatin can improve survival in HCC patients or not.

## Eligibility

- **Minimum age:** 35 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Male or female patients \> 35 years and \<=55 years of age.
2. confirmed case (patients with HCC)
3. Tumors can be radical removed and resection volume was 50% to 70%.
4. Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal value,alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value.
5. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. Hbg ≥ 90g/L, WBC ≥ 3.000 cells/mm³,platelets ≥ 80.000 cells/mm³.
6. Karnofsky Performance Score performance over 60.
7. Patients who can understand this trial and have signed information consent.

Exclusion Criteria:

1. Patients who have undergone previous treatment by Ulinastatin.
2. Patients with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect the treatment of liver cancer.
3. Patients with other diseases which may affect the treatment mentioned here.
4. Patients with medical history of other malignant tumors.
5. Subjects participating in other clinical trials.
6. Extrahepatic metastasis, portal vein or other major vascular involvement. liver function: Child B C.
7. Patients would not sign the consent to the trial.
```

## Arms

- **Diammonium glycyrrhizinate** (ACTIVE_COMPARATOR) — Conventional drugs protect liver
- **Ulinastatin** (EXPERIMENTAL) — Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)

## Interventions

- **Ulinastatin** (DRUG) — Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
- **Diammonium glycyrrhizinate** (DRUG)

## Primary Outcomes

- **the overall survival rate of each group** _(time frame: 3 years)_

## Locations (1)

- Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai Municipality, China

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.eastern hepatobiliary surgery hospital|shanghai|shanghai municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01643447.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01643447*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*